Actualités 17. Apr. 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
Innovation Switzerland Innovation Parks Switzerland Innovation’s technology parks are the ideal location for research-oriented companies to develop their next groundbreaking or highly p...
Aktuell 15. Mai 2024 Allegria Therapeutics nimmt 3,5 Millionen Dollar in Seed-Runde ein Allegria Therapeutics hat eine Seed-Finanzierung von 3,5 Millionen Dollar durch den Gründungsinvestor Forty51 Ventures erhalten. Das Biotech-Star...
News 18. März 2024 Neuria enters Vanguard Accelerator to gameify healthier lifestyles Neuria Digital Therapeutics has become the inaugural start-up of 2024 to be embraced by the Vanguard Accelerator program.
Actualités 30. Apr. 2024 Les Grands Titres de Suisse occidentale (Avril 2024) De percées biotechnologiques à la transformation des essais cliniques, en passant par des avancées dans le domaine des matériaux écologiques et d...
Innovation Switzerland Innovation Parks Switzerland Innovation’s technology parks are the ideal location for research-oriented companies to develop their next groundbreaking or highly p...
News 17. Apr. 2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
Innovation Switzerland Innovation Parks Switzerland Innovation’s technology parks are the ideal location for research-oriented companies to develop their next groundbreaking or highly p...
News 15. Mai 2024 Allegria Therapeutics raises 3.5 million dollars in seed financing round Allegria Therapeutics has received seed funding of 3.5 million dollars from the founding investor Forty51 Ventures. The biotech startup is develo...
News 06. Mai 2024 EY reports growth of 53 percent for investments in Switzerland Foreign investments in Europe fell by 4 percent in 2023. However, investments in Switzerland were up by 53 percent. These findings were reported ...
News 30. Apr. 2024 Top Stories from Western Switzerland (April 2024) From biotech breakthroughs and the transformation of clinical trials to advancements in eco-friendly materials and renewable energy initiatives, ...
News 07. Aug. 2023 CDR-Life receives milestone payment CDR-Life has reached a second milestone linked to the development of its drug to combat an irreversible retinal disease. This entitles the biotec...
Aktuell 07. Aug. 2023 CDR-Life erhält Meilensteinzahlung CDR-Life hat bei der Entwicklung seines Therapeutikums gegen eine irreversible Erkrankung der Netzhaut ein zweites Etappenziel erreicht. Das bere...
News 18. Okt. 2023 BioArk Monthey’s third building signifies exponential growth in the life sciences sector With two decades under its belt, the BioArk site in Monthey continues to cement its position as a front-runner in life sciences.
News 25. Okt. 2023 Mecaplast Swiss, 50 years of innovation in the canton of Fribourg With a rich history spanning five decades, Mecaplast Swiss has consistently proven itself as a leader in the plastic injection industry, particul...
News 22. Jan. 2024 DISCO Pharmaceuticals secures seed funding of 20 million euros DISCO Pharmaceuticals has secured seed funding of 20 million euros and officially launched the business. The team was the first to develop a meth...
News 23. Apr. 2024 Swibrace advances to clinical phase with innovative 3D-printed wrist braces Swibrace, in partnership with the Inselspital in Bern, moves its customized wrist braces into clinical phase, enhancing fracture treatment throug...
Actualités 12. Febr. 2024 Transmutex reçoit CHF 20 millions pour sa technologie révolutionnaire d’énergie nucléaire La société genevoise Transmutex a levé plus de CHF 20 millions pour accélérer le développement de son système innovant d’énergie nucléaire.